Charles River Laboratories Debt to Equity Ratio 2006-2018 | CRL

Current and historical debt to equity ratio values for Charles River Laboratories (CRL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Charles River Laboratories debt/equity for the three months ending September 30, 2018 was 1.32.
Charles River Laboratories Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $1.65B $1.26B 1.32
2018-06-30 $1.80B $1.19B 1.52
2018-03-31 $1.13B $1.14B 0.99
2017-12-31 $1.11B $1.05B 1.06
2017-09-30 $1.16B $1.03B 1.13
2017-06-30 $1.12B $0.97B 1.16
2017-03-31 $1.17B $0.88B 1.33
2016-12-31 $1.21B $0.84B 1.44
2016-09-30 $1.23B $0.87B 1.41
2016-06-30 $1.33B $0.84B 1.59
2016-03-31 $0.84B $0.78B 1.07
2015-12-31 $0.85B $0.74B 1.15
2015-09-30 $0.84B $0.71B 1.18
2015-06-30 $0.76B $0.71B 1.07
2015-03-31 $0.76B $0.67B 1.13
2014-12-31 $0.74B $0.68B 1.10
2014-09-30 $0.76B $0.67B 1.12
2014-06-30 $0.78B $0.68B 1.16
2014-03-31 $0.61B $0.70B 0.88
2013-12-31 $0.64B $0.64B 1.00
2013-09-30 $0.62B $0.66B 0.95
2013-06-30 $0.62B $0.65B 0.95
2013-03-31 $0.52B $0.63B 0.82
2012-12-31 $0.53B $0.60B 0.87
2012-09-30 $0.54B $0.60B 0.91
2012-06-30 $0.55B $0.57B 0.98
2012-03-31 $0.68B $0.56B 1.22
2011-12-31 $0.70B $0.53B 1.33
2011-09-30 $0.72B $0.54B 1.33
2011-06-30 $0.73B $0.59B 1.24
2011-03-31 $0.76B $0.56B 1.35
2010-12-31 $0.67B $0.69B 0.97
2010-09-30 $0.70B $1.04B 0.68
2010-06-30 $0.41B $1.39B 0.29
2010-03-31 $0.44B $1.38B 0.32
2009-12-31 $0.46B $1.37B 0.33
2009-09-30 $0.46B $1.35B 0.34
2009-06-30 $0.49B $1.28B 0.38
2009-03-31 $0.47B $1.22B 0.39
2008-12-31 $0.48B $1.24B 0.39
2008-09-30 $0.30B $1.95B 0.16
2008-06-30 $0.31B $1.95B 0.16
2008-03-31 $0.48B $1.91B 0.25
2007-12-31 $0.49B $1.86B 0.26
2007-09-30 $0.49B $1.80B 0.27
2007-06-30 $0.51B $1.73B 0.30
2007-03-31 $0.53B $1.64B 0.32
2006-12-31 $0.55B $1.60B 0.34
2006-09-30 $0.58B $1.55B 0.37
2006-06-30 $0.57B $1.64B 0.35
2006-03-31 $0.27B $1.74B 0.16
2005-12-31 $0.26B $1.83B 0.14
2005-09-30 $0.30B $1.79B 0.17
2005-06-30 $0.33B $1.73B 0.19
2005-03-31 $0.59B $1.52B 0.39
Sector Industry Market Cap Revenue
Medical Medical Services $6.295B $1.858B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.055B 11.38
ICON (ICLR) Ireland $7.186B 22.52
PRA Health Sciences (PRAH) United States $6.536B 26.68
HealthEquity (HQY) United States $5.293B 110.78
Premier (PINC) United States $5.276B 17.90
INC Research Holdings (SYNH) United States $5.161B 20.83
Teladoc (TDOC) United States $4.142B 0.00
NovoCure (NVCR) Jersey $2.933B 0.00
AMN Healthcare Services Inc (AMN) United States $2.890B 19.83
BioTelemetry (BEAT) United States $2.126B 37.55
Medpace Holdings (MEDP) United States $1.974B 24.42
Healthways (TVTY) United States $1.472B 18.10
Intrexon (XON) United States $1.393B 0.00
CareDx (CDNA) United States $1.165B 0.00
IKang Healthcare (KANG) China $1.161B 57.66
Natera (NTRA) United States $1.037B 0.00
China Cord Blood (CO) China $0.794B 21.06
Apollo Medical Holdings (AMEH) United States $0.742B 0.00
Surgery Partners (SGRY) United States $0.641B 0.00
Establishment Labs Holdings (ESTA) $0.536B 0.00
Civitas Solutions (CIVI) United States $0.525B 10.34
OncoCyte (OCX) United States $0.069B 0.00
Interpace Diagnostics (IDXG) United States $0.034B 0.00
Cancer Genetics (CGIX) United States $0.014B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00